Science
Mechanism of Action
This ingredient functions as a cellular signal molecule, stimulating accelerated skin cell division, growth, and differentiation. It significantly enhances the production and secretion of essential extracellular macromolecules like hyaluronic acid and glycoproteins. By boosting keratinocyte expression and growth, it aids in wound healing, increases collagen synthesis, and strengthens the skin's natural barrier function, leading to comprehensive skin revitalization.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 A 2012 study using a serum containing a bioengineered epidermal growth factor demonstrated statistically significant improvements in the appearance of fine lines, wrinkles, skin texture, pore size, and various dyschromatic conditions within one month, with sustained improvements over three months. This study also noted enhanced skin regeneration, wrinkle reduction, and improved skin tone through stimulated collagen production, firmness, and elasticity.
- 02 A manufacturer-sponsored clinical trial observed notable increases in skin elasticity, luminosity, and brightness, alongside a reduction in skin sagging after 30 days of using a product containing sh-oligopeptide-1. However, this study acknowledged imprecise methods and the absence of a properly defined control group.
Transparency
Dusting Analysis
The Formula
Formulation
Stability
This ingredient, when formulated as SpecBio™EGF Plus (CE85), exhibits good stability at room temperature, eliminating the need for cold storage. It should be incorporated into formulations during the final step at temperatures below 45℃ to maintain its integrity.
Safety
Safety Profile
SH-Oligopeptide-1 (often used interchangeably in research with SH-Oligopeptide-85) is generally considered safe, compatible, and biodegradable for cosmetic use in various concentrations. While it is mitogenic (stimulates cell proliferation), it is not recognized as mutagenic (does not cause cancerous cell alterations). However, long-term risks remain unknown. Caution is advised for individuals with existing skin cancer risk factors or psoriasis, as EGF could potentially accelerate cancer cell spread or exacerbate psoriasis. Active recombinant human EGF (hr-EGF) is not authorized as a medication in topical applications outside of clinical trials, classifying it as a potent unauthorized drug in some contexts.
Your Skin
Skin Compatibility
Our Assessment
Verdict
SH-Oligopeptide-85 is a valuable ingredient, demonstrated to significantly improve multiple signs of aging and promote skin regeneration, though its long-term safety and regulatory status warrant careful consideration.
Related
Similar Ingredients
Finding similar ingredients…